• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Aevi Genomic Medicine, Inc. is a medical technology company, which focuses on finding treatments for rare and orphan diseases, with a particular focus on pediatrics, following a genomics medicine strategy. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.
| Market Cap | 10.752 Million | Shares Outstanding | 64.77 Million | Avg 30-day Volume | 3.071 Million |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.19 |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -19.117 Million |
| Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | 7.323 Million |
| Current Ratio | 0.655 | EPS Growth | 0.44 | Quick Ratio | 0.56 |
| 1 Yr BETA | 0.9558 | 52-week High/Low | 0.0 / | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 30.0102 | Altman Z-Score | -151.6268 | Free Cash Flow to Firm | -15.467 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
COLA MICHAEL F CHIEF EXECUTIVE OFFICER |
|
175,746 | 2020-06-09 | 0 |
|
No longer subject to file | 2020-02-03 | 0 | |
|
No longer subject to file | 2020-02-03 | 0 | |
|
No longer subject to file | 2020-02-03 | 0 | |
|
No longer subject to file | 2020-02-03 | 0 | |
|
No longer subject to file | 2020-02-03 | 0 | |
|
NEIL GARRY ARTHUR CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2020-02-03 | 0 |
|
No longer subject to file | 2020-02-03 | 0 | |
|
No longer subject to file | 2020-02-03 | 0 | |
|
MCINAW MICHAEL INTERIM CFO |
|
No longer subject to file | 2020-02-03 | 0 |
|
12,946,900 | 2019-12-19 | 0 | |
|
PIPER BRIAN CFO & CORPORATE SECRETARY |
|
0 | 2018-06-14 | 0 |
|
78,134 | 2017-10-17 | 0 | |
|
5,179,819 | 2017-09-01 | 0 | |
|
0 | 2016-04-15 | 0 | |
|
APPLEBAUM SCOTT CHIEF LEGAL OFFICER |
|
0 | 2016-04-15 | 0 |
|
0 | 2015-02-18 | 0 | |
|
0 | 2015-02-18 | 0 | |
|
LEAMAN JOHN HAROLD CHIEF FINANCIAL OFFICER |
|
0 | 2015-02-18 | 0 |
|
PEARLMAN ANDREW PRESIDENT AND CEO |
|
0 | 2011-09-22 | 0 |
|
66,077 | 2011-09-07 | 0 | |
|
DELLIO CLARENCE L CHIEF OPERATING OFFICER |
|
0 | 2011-07-01 | 0 |
|
STERN BARUCH CHIEF SCIENTIFIC OFFICER |
|
29,726 | 2011-05-11 | 0 |
|
RIVER CHARITABLE REMAINDER UNITRUST F/B/O ISAAC BLECH |
|
1,663,121 | 2011-04-13 | 0 |
|
636,975 | 2011-04-13 | 0 | |
|
636,975 | 2011-04-13 | 0 | |
|
606,555 | 2011-04-13 | 0 | |
|
0 | 2011-04-07 | 0 | |
|
0 | 2011-04-07 | 0 | |
|
BELLOMO STEPHEN CHIEF OPERATING OFFICER |
|
0 | 2011-04-07 | 0 |
|
BELLIN PHYLLIS K. SEE REMARKS |
|
10,664 | 2011-04-07 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
